Variable | 23 Patients No (%) |
---|---|
Age at diagnosis (years) | |
Range (Mean ± SD) | 52–79 (66.65 ± 7.36) |
Prostate volume (cc) | 25.73–109.35 (60.67 ± 21.18) |
PSA at diagnosis (ng/ml) | |
Range (Mean ± SD) | 5.03–34.78 (13.1 ± 8.5) |
< 10 | 11 (47.8%) |
10–20 | 7 (30.4%) |
> 20 | 5 (21.7%) |
Gleason score | |
3 + 4 | 10 (43.5%) |
4 + 3 | 5 (21.7%) |
≥ 4 + 4 | 8 (34.8%) |
T stage | |
cT2b | 4 (17.4%) |
cT2c | 14 (60.9%) |
cT3a | 2 (8.7%) |
cT3b | 1 (4.3%) |
cT4 | 2 (8.7%) |
N Stage | |
N0 | 23 (100%) |
N+ | 0 |
ADT | |
Yes | 10 (43.5%) |
No | 13 (56.5%) |
Hydrogel spacer | |
Yes | 15 (65.2%) |
No | 8 (34.8%) |